Compare Agilent Technologies Inc (A) vs C3.ai Inc (AI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs C3.ai Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while C3.ai Inc trades at $10.62 (market cap $1.59B). The key difference: Agilent Technologies Inc is far larger — about 26.4× C3.ai Inc's market cap, and Agilent Technologies Inc pays a 0.69% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals.
| A | AI | |
|---|---|---|
Market Cap | $42.00B | $1.59B |
Sector | Health | Technology |
52-Week High | $157.20 | $19.66 |
52-Week Low | $110.24 | $7.76 |
Enterprise Value | $43.55B | $1.02B |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
C3.ai (AI) trades at $10.22, up 3.65% with a bullish technical signal. The company shows revenue growth to $389M in 2025 but continues significant losses with a -187.95% net income margin. Recent recognition as a leader in AI platforms by Forrester Research (August 10, 2026) provides positive momentum, though cash flow remains negative. Analyst consensus is mixed with 21% buy ratings and a $10.20 price target slightly below current levels.
The outlook remains challenging with persistent losses offset by strong market positioning in enterprise AI. Investment opportunity lies in the company's leadership recognition and sector growth potential, while risks include unsustainable cash burn and competitive pressures. The stock faces near-term resistance at $11 with support at $10.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →
